Mostrando entradas con la etiqueta NEFROLOGIA. Mostrar todas las entradas
Mostrando entradas con la etiqueta NEFROLOGIA. Mostrar todas las entradas
sábado, 5 de noviembre de 2011
lunes, 13 de diciembre de 2010
CANCER RENAL
TIPO: REVISION
FORMATO: PDF
IDIOMA: ESPAÑOL
DESCARGA DIRECTA: DESCARGAR
domingo, 12 de diciembre de 2010
USO DE LA BIOPSIA RENAL EN LA ANCIANIDAD
TIPO: REVISION
FORMATO: PDF
IDIOMA: INGLES
DESCARGA DIRECTA: DESCARGAR
sábado, 11 de diciembre de 2010
NUEVAS TERAPIAS EN EL CANCER DE CELULAS RENALES
TIPO: REVISION
FORMATO: PDF
IDIOMA: INGLES
DESCARGA DIRECTA: DESCARGAR
martes, 7 de diciembre de 2010
IRC: TRATAMIENTOS SUSTITUTIVOS, TIPOS E INDICACIONES. TRASPLANTE RENAL
TIPO: REVISION
FORMATO: PDF
IDIOMA: ESPAÑOL
DESCARGA DIRECTA. DESCARGAR
sábado, 4 de diciembre de 2010
CANCER RENAL
TIPO: REVISION
FORMATO: PDF
IDIOMA: INGLES
DESCARGA DIRECTA: DESCARGAR
miércoles, 1 de diciembre de 2010
HEMODIALISIS
TIPO: REVISION
FORMATO: PDF
DESCARGA DIRECTA: DESCARGAR
martes, 30 de noviembre de 2010
domingo, 28 de noviembre de 2010
USO DE AMINOGLUCOSIDOS EN FALLA RENAL
Revisión publicada en Indian Journal of Nephrology el 2010
TIPO: REVISION
FORMATO: PDF
DESCARGA DIRECTA: DESCARGAR
martes, 29 de julio de 2008
HIPONATREMIA: GUIAS DE TRATAMIENTO
Guias publicada en el 2007 en American Journal of Medicine.
INTRODUCCION
Although hyponatremia is a common, usually mild, and relatively asymptomatic disorder of electrolytes, acute severe hyponatremia can cause substantial morbidity and mortality, particularly in patients with concomitant disease. In addition, overly rapid correction of chronic hyponatremia can cause severe neurologic deficits and death, and optimal treatment strategies for such cases are not established. An expert panel assessed the potential contributions of aquaretic nonpeptide small-molecule arginine vasopressin receptor (AVPR) antagonists to hyponatremia therapies. This review presents their conclusions, including identification of appropriate treatment populations and possible future indications for aquaretic AVPR antagonists.
TIPO: GUIAS
FORMATO: PDF
DESCARGA DIRECTA: DOWNLOAD
Although hyponatremia is a common, usually mild, and relatively asymptomatic disorder of electrolytes, acute severe hyponatremia can cause substantial morbidity and mortality, particularly in patients with concomitant disease. In addition, overly rapid correction of chronic hyponatremia can cause severe neurologic deficits and death, and optimal treatment strategies for such cases are not established. An expert panel assessed the potential contributions of aquaretic nonpeptide small-molecule arginine vasopressin receptor (AVPR) antagonists to hyponatremia therapies. This review presents their conclusions, including identification of appropriate treatment populations and possible future indications for aquaretic AVPR antagonists.
TIPO: GUIAS
FORMATO: PDF
DESCARGA DIRECTA: DOWNLOAD
domingo, 27 de julio de 2008
INSUFICIENCIA RENAL CRONICA: MANEJO
Revisión: Disease Management in Chronic Kidney Disease publicada en febrero del 2008 en Advances in Chronic Kidney Disease de The National Kidney Foundation, Inc.
INTRODUCCION
Chronic kidney disease (CKD) is a growing health problem of epidemic proportions both in the United States and worldwide. The care of CKD patients, before and after starting dialysis, remains highly fragmented resulting in suboptimal clinical outcomes and high costs, creating a high burden of disease on patients and the health care system. Disease management (DM) is an approach to coordinating care for this complex population of patients that has the promise of improving outcomes and constraining costs. For CKD patients not yet on dialysis, the major goals of a DMprogram are (1) early identification of CKD patients and therapy to slow the progression of CKD, (2) identification and management of the complications of CKD per se, (3) identification and management of the complications of comorbid conditions,
and (4) smooth transition to renal replacement therapy. For those CKD patients on dialysis, focused attention on avoidable hospitalizations is a key to a successful DM program. Multidisciplinary collaboration among physicians (nephrologist, primary care physician, cardiologist, endocrinologist, vascular surgeons, and transplant physicians) and participating caregivers (nurse, pharmacist, social worker, and dietician) is critical as well. There are several potential barriers to the successful implementation of a CKD/end-stage renal disease DM program, including lack of awareness of the disease state among patients and health care providers, late identification and referrals to a nephrologist, complex fragmented care delivered by multiple providers in many different sites of care, and reimbursement that does not align incentives for all involved. Recent experience suggests that these barriers can be overcome, with DM becoming a promising approach for improving outcomes for this vulnerable population.
TIPO: REVISION
FORMATO: PDF
DESCARGA DIRECTA: DOWNLOAD
Chronic kidney disease (CKD) is a growing health problem of epidemic proportions both in the United States and worldwide. The care of CKD patients, before and after starting dialysis, remains highly fragmented resulting in suboptimal clinical outcomes and high costs, creating a high burden of disease on patients and the health care system. Disease management (DM) is an approach to coordinating care for this complex population of patients that has the promise of improving outcomes and constraining costs. For CKD patients not yet on dialysis, the major goals of a DMprogram are (1) early identification of CKD patients and therapy to slow the progression of CKD, (2) identification and management of the complications of CKD per se, (3) identification and management of the complications of comorbid conditions,
and (4) smooth transition to renal replacement therapy. For those CKD patients on dialysis, focused attention on avoidable hospitalizations is a key to a successful DM program. Multidisciplinary collaboration among physicians (nephrologist, primary care physician, cardiologist, endocrinologist, vascular surgeons, and transplant physicians) and participating caregivers (nurse, pharmacist, social worker, and dietician) is critical as well. There are several potential barriers to the successful implementation of a CKD/end-stage renal disease DM program, including lack of awareness of the disease state among patients and health care providers, late identification and referrals to a nephrologist, complex fragmented care delivered by multiple providers in many different sites of care, and reimbursement that does not align incentives for all involved. Recent experience suggests that these barriers can be overcome, with DM becoming a promising approach for improving outcomes for this vulnerable population.
TIPO: REVISION
FORMATO: PDF
DESCARGA DIRECTA: DOWNLOAD
MECANISMO DE LA NEFROPATIA DIABETICA: ROL DE LA HIPERTENSION
Revision publicada en septiembre del 2006 en la revista Hypertension de la American Heart Association.
INTRODUCCION
Diabetic nephropathy is a major microvascular complication of diabetes, representing the leading cause of endstage renal disease in the Western world, and a major cause of morbidity and mortality in both type 1 and type 2 diabetic subjects. Clinical hallmarks of diabetic nephropathy include a progressive increase in urinary albumin excretion and a decline in glomerular filtration rate (GFR), which occur in association with an increase in blood pressure, ultimately leading to endstage renal failure. These renal functional changes develop as a consequence of structural abnormalities, including glomerular basement membrane thickening, mesangial expansion with extracellular matrix accumulation, changes in glomerular epithelial cells (podocytes), including a decrease in number and/or density, podocyte foot process broadening and effacement, glomerulosclerosis, and tubulointerstitial fibrosis.
TIPO: REVISION
FORMATO: PDF
DESCARGA DIRECTA: DOWNLOAD
Diabetic nephropathy is a major microvascular complication of diabetes, representing the leading cause of endstage renal disease in the Western world, and a major cause of morbidity and mortality in both type 1 and type 2 diabetic subjects. Clinical hallmarks of diabetic nephropathy include a progressive increase in urinary albumin excretion and a decline in glomerular filtration rate (GFR), which occur in association with an increase in blood pressure, ultimately leading to endstage renal failure. These renal functional changes develop as a consequence of structural abnormalities, including glomerular basement membrane thickening, mesangial expansion with extracellular matrix accumulation, changes in glomerular epithelial cells (podocytes), including a decrease in number and/or density, podocyte foot process broadening and effacement, glomerulosclerosis, and tubulointerstitial fibrosis.
TIPO: REVISION
FORMATO: PDF
DESCARGA DIRECTA: DOWNLOAD
Suscribirse a:
Entradas (Atom)